Tonix Pharmaceuticals stock halted ahead of FDA approval news
Smith & Nephew SNATS Inc. stock reached a significant milestone, hitting a 52-week high at 36.56 USD. This marks a notable achievement for the company, reflecting a strong performance over the past year. The stock’s ascent to this level underscores a 21.37% increase in its value over the last 12 months. This upward trajectory highlights investor confidence and the company’s solid market position, supported by its 49-year track record of consistent dividend payments. According to InvestingPro analysis, the stock is currently showing signs of being overbought, with additional insights available through 12 exclusive ProTips and comprehensive financial metrics in the Pro Research Report.
In other recent news, Smith & Nephew has announced its plans to release its second quarter and first half 2025 financial results on August 5, 2025. This announcement will be accompanied by a conference call for financial analysts. In 2024, Smith & Nephew reported annual sales of $5.8 billion. Additionally, the company has appointed David King as an independent Non-Executive Director, effective July 1, 2025. King will also serve on the Compliance & Culture and Remuneration Committees. He brings a wealth of experience from his roles at Fortis Life Sciences and other healthcare companies. His notable past positions include executive chair and CEO at Laboratory Corporation of America. These developments highlight recent changes and upcoming financial disclosures for Smith & Nephew.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.